uploads/2018/09/Chart-005-Revenue-Growth-Rate-1.jpg

Exploring Pharmaceutical Stocks’ Revenue Growth Rates

By

Updated

Pharmaceutical stocks

In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

The chart above compares the revenue growth rates of these companies since the first quarter of 2017.

Article continues below advertisement

Eli Lilly

Eli Lilly reported a ~9.1% rise in its second-quarter revenue. Its reported revenue rose to ~$6.4 billion in the quarter compared to $5.8 billion in the second quarter of 2017.

Pfizer

Pfizer reported a ~4.4% rise in its second-quarter revenue. Its reported revenue rose to ~$13.5 billion in the quarter compared to $12.9 billion in the second quarter of 2017.

Article continues below advertisement

Merck & Co.

Merck & Co. reported a ~5.4% rise in its second-quarter revenue. Its reported revenue rose to ~$10.5 billion in the quarter compared to $9.9 billion in the second quarter of 2017.

Allergan

Allergan reported a ~2.3% rise in its second-quarter revenue. Its reported revenue rose to ~$4.1 billion in the quarter compared to $4.0 billion in the second quarter of 2017.

GlaxoSmithKline

GlaxoSmithKline reported a marginal fall of ~0.14% in its second-quarter revenue. Its reported revenue fell to ~7.31 billion British pounds in the quarter compared to its revenue of 7.32 billion pounds in the second quarter of 2017.

We’ll discuss the details of these companies’ quarterly performances and 2018 estimates in the coming articles.

The Health Care Select Sector SPDR ETF (XLV) holds 5.2% in Merck & Co., 2.8% in Eli Lilly, 6.7% in Pfizer, and 1.8% in Allergan.

Advertisement

More From Market Realist